|
Almeida Capital is pleased to be a premier sponsor of AltAssets
|
FREE newsletter RSS
INTELLIGENCE
RECRUITMENT
KNOWLEDGE BANK
EVENTS
SECTOR ANALYSIS
HEDGE FUNDS
|
Click here for printer friendly page
CapMan Life Science IV closes on €54m24/05/2007. Source: AltAssets. 
 CapMan Life Science IV has closed on €54m. The fund invests in medical technology and service companies, mainly in the Nordic countries.
Eight institutional investors have committed to invest in CapMan Life Science IV. Two of them were new investors. CapMan committed €10m to its new investment vehicle.
Jerome Bouix, partner and head of fundraising, IR and communications at CapMan, said, 'We are pleased with the fundraising outcome and especially happy for having been able to expand our life science investor base outside the Nordic countries and to welcome new investors to the fund. During CapMan Life Science IV's fundraising period the investor appetite has mainly been directed at buy-out funds and the investors' venture allocations have been limited.'
CapMan Life Science IV has already invested in three companies: Neoventa Medical, ProstaLund and QuickCool.
Jan Lundahl, senior partner and head of CapMan Life Science, said, 'The new fund has started investment operations very actively and the number of potential investment targets within the fund's investment focus has remained at a good level both in terms of quantity and quality. Our team sees over 80 per cent of the Nordic investment opportunities within the fund's focus and a significant number of potential deals coming from the rest of Europe. In the next few years the fund will make investments in six to eight new companies.'
CapMan manages Nordic buy-out, mezzanine, technology, life science and real estate funds with approximately €3bn in total capital.
Copyright © 2007 AltAssets
|
 
|
|
|
